Mifepristone significantly reduced A1C in patients with hypercortisolism and difficult-to-control type 2 diabetes, according to results from the CATALYST study presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. The group taking mifepristone had a mean A1C reduction of 1.47% at 24 weeks compared with 0.15% for the group receiving a placebo.
Full Story: Healio (free registration) (12/30)